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a b s t r a c t 
ETO2 is a component of a protein complex containing master regulators of hematopoiesis, including 
GATA-1 and SCL / TAL1, and also has RNA binding properties. Although ETO2 has been reported to repress
GATA-1 target genes through histone deacetylation of the target gene loci in erythroid cells, little is 
known about the contribution of ETO2 to microRNA (miRNA) regulation. Here, we conducted miRNA 
proﬁling in ETO2-overexpressing and ETO2-silenced K562 cells. The analysis suggests that ETO2 pos- 
itively regulates the abundance of mature miRNAs, including miR-21, miR-29b and let-7e. Our data 
suggest a novel mode of ETO2-mediated target gene repression via effects on miRNA expression. 
C © 2013 The Authors. Published by Elsevier B.V. on behalf of Federation of European Biochemical 
Societies. Open access under CC BY license.. Introduction 
The differentiation of hematopoietic stem cells (HSCs) into spe- 
iﬁc progenitor cells, and ultimately into diverse blood cell types, is 
ontrolled by various transcription factors, represented by the GATA 
actors [ 1 ]. In the context of erythropoiesis, GATA-1 regulates the ex- 
ression of various erythroid-related genes by recognizing the DNA 
inding consensus sequence (A / T)GATA(A / G) through dual zinc ﬁn- 
er motifs, which are characteristic of the GATA family [ 2 ]. GATA-1 
orms a complex with another master regulator of hematopoiesis, 
he basic-helix-loop-helix transcription factor SCL / TAL1 [ 1 , 3 , 4 ]. SCL / 
AL1 is a master regulator of hematopoiesis that binds E-boxes and 
on-DNA binding components of LMO2, LDB1, and ETO2 [ 1 , 3 –9 ]. 
ETO2 (also known as MTG16 or CBFA2T3 ) confers transcriptional 
epression mediated by GATA-1–SCL / TAL1 complex through interac- 
ion with histone deacetylases (HDACs) [ 10 ]. To assess the impact of 
TO2 on GATA-1 targets in erythroid cells, we previously conducted Abbreviations: ETO2 (CBFA2T3), core-binding factor, runt domain, alpha subunit 2, 
ranslocated to, 3; LMO2, LIM domain only 2; CBF1, core-binding factor 1; RPMI, Roswell 
ark Memorial Institute; IMDM, Iscove ’ s Modiﬁed Dulbecco ’ s Media; IL-3, interleukin 
; SCF, stem cell factor; siRNA, small interfering RNA; cDNA, complementary DNA. 
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ttp://dx.doi.org/10.1016/j.fob.2013.10.004 mRNA expression proﬁling analyses and demonstrated that ETO2 re- 
presses a relatively small subset of direct GATA-1 targets [ 11 , 12 ]. Be- 
yond the association with GATA–SCL / TAL1 complex, although ETO2 
has also been reported to interact with the intracellular domain of 
Notch1 and the Notch-regulated transcription factor CBF1 [ 13 ] as 
well as T-cell factor 4 (TCF4), which is involved in Wnt signaling [ 14 ], 
the regulatory mechanism mediated by ETO2 remains to be fully elu- 
cidated. 
The regulation of erythroid differentiation by noncoding RNAs 
(ncRNAs) is becoming well understood [ 15 ]. ncRNAs are broadly clas- 
siﬁed into housekeeping RNAs (rRNAs, tRNAs, and snoRNAs), small 
and long ncRNAs ( < 200 and > 200 bases, respectively), siRNAs, PIWI- 
interacting RNAs (piRNAs), and microRNAs (miRNAs) [ 15 ]. Among 
these ncRNAs, miRNAs are now universally recognized as an exten- 
sive and ubiquitous class of regulatory molecules [ 16 ]. Several studies 
demonstrated that numerous miRNAs are induced or repressed dur- 
ing erythroid differentiation [ 17 –21 ]. GATA-1 directly regulates the 
expression of miR-144 and miR-451, both of which are intimately 
involved in the erythroid phenotype [ 18 ]. Furthermore, expression 
data-based correlation analysis revealed that Lmo2–GATA-1 is an im- 
portant regulatory module for miRNA expression [ 22 ]. These ﬁndings 
suggest that GATA-1, or possibly GATA-1–SCL / TAL1 complex, plays 
an important role in miRNA regulation during erythroid differentia- 
tion. Intriguingly, it has also been demonstrated that ETO2 has RNA- 
binding properties [ 23 ], suggesting that ETO2 may regulate its targets 
by affecting an RNA component in erythroid cells. 
The present study was performed to improve our knowledge re- 
garding the role of ETO2 in miRNA regulation in erythroid cells using an Biochemical Societies. Open access under CC BY license.



























































































 the K562 erythroleukemia cell line and cord blood CD34-positive cell-
derived primary erythroblasts. 
2. Materials and methods 
2.1. Cell culture 
Human K562 erythroleukemia cells were maintained in RPMI-
1640 medium containing 10% fetal bovine serum (Biowest) and 1%
penicillin–streptomycin (Sigma). To obtain primary erythroblasts,
cord blood CD34-positive cells were suspended into erythroid IMDM
medium containing IL-3 (50 ng / mL), SCF (50 ng / mL), and erythro-
poietin (EPO) (2 IU / mL) [ 12 ]. The use of cord blood samples for the
study was approved by the ethics committee of Tohoku University.
Ethical considerations according to the declaration of Helsinki were
followed. 
2.2. Gene transfer and vectors 
ETO2 mRNA was cloned into pcDNA( −) / Myc-His vector (Invitro-
gen). ETO2 overexpression in K562 cells was conducted with Amaxa
Nucleofector kit solution V (Amaxa Biosystems), as described previ-
ously [ 12 ]. For ETO2 overexpression in cord blood CD34-positive cell-
derived primary erythroblasts, retroviral vector (pBABE-puro) was
used as described previously [ 12 ]. Brieﬂy, CD34-positive cells were
incubated with the viral supernatant for infection, and the cells were
differentiated for 4 days with erythroid medium containing 1 μg / mL
puromycin (Sigma) for selection of transduced cells. 
2.3. Silencing of gene expression by siRNA 
For siRNA-mediated transient human ETO2 knockdown in K562
cells, siGENOME human CBFA2T3 siRNA – SMART pool (Thermo Sci-
entiﬁc Dharmacon) was used. The antisense sequences of the siRNA
for human CBFA2T3 were UGAAUGAGGUGAAGCGGCA, CAGCGGAG-
GUGAAGACGCA, CCAAAGAGAACGGGUCAGA, CAUUGACGAUCGAG-
GAGUU. As a negative control, siGENOME non-targeting siRNA pool
#1 (Thermo Scientiﬁc Dharmacon) was used. siRNA was transfected
into K562 cells using Amaxa Nucleofector kit solution V with the T-
016 program (Amaxa Biosystems). siRNA was transfected twice at 0
and 24 h, and the cells were harvested at 48 h. 
2.4. Real-time quantitative RT-PCR 
Total RNA was used to synthesize cDNA with Superscript II
(Invitrogen) as described previously [ 7 , 10 , 12 ]. Product ampliﬁ-
cation was monitored by measuring SYBR Green ﬂuorescence
and normalized relative to GAPDH mRNA. Primer sequences were
as follows; ETO2 Forward: 5 ′ -ATTGACGATCGAGGAGTTTCAT-
3 ′ , Reverse: 5 ′ -GCAGCAAGGGCAGGTTT-3 ′ , GAPDH For-
ward: 5 ′ -GAAGGTCGGAGTCAACGGATTT-3 ′ , Reverse: 5 ′ -
GAATTTGCCATGGGTGGAAT-3 ′ . 
For quantiﬁcation of miRNA expression, cDNA was synthesized
from total RNA using a miRCURY LNA TM Universal cDNA syn-
thesis kit (EXIQON), and subsequently analyzed with miRCURY
LNA TM PCR primer set and SYBR Green master mix according to
the manufacturer’s instructions (EXIQON). The primers used in
the study were; hsa-miR-21 (MIMAT0000076), hsa-miR-29b (MI-
MAT0000100), hsa-let-7e (MIMAT0000066), hsa-miR-19b-1* (MI-
MAT0004491), hsa-miR-20a (MIMAT0000075) and hsa-miR-15b (MI-
MAT0000417). Product accumulation was monitored by measuring
SYBR Green ﬂuorescence and normalized relative to the RNA spike-
in (UniSp6 CP), and changes in expression were quantiﬁed by the
 threshold cycle ( C γ) method. Control reactions lacking cDNA
synthase yielded little to no signal. 2.5. miRNA proﬁling analysis and miRNA target prediction analysis 
Human miRNA Oligo chip V16.1.0.0 (Toray) was used according
to the manufacturer’s protocol. For global normalization, background
value was subtracted, and subsequently adjusted to the average signal
value of 25. 
2.6. Western blotting analysis 
Western blotting analysis was conducted as described previously
[ 7 , 12 ]. 
2.7. Antibodies 
Antibodies to ETO2 (C-20) and α-Tubulin (CP06) were obtained
from Santa Cruz Biotechnology and Calbiochem, respectively. 
2.8. Statistics 
Statistical signiﬁcance was assessed by two-sided Student’s t test.
In all analyses, P < 0.05 was taken to indicate statistical signiﬁcance. 
3. Results and discussion 
We conducted miRNA proﬁling using identical RNA samples from
ETO2-overexpressing K562 cells as described previously [ 12 ]. The
analysis revealed that ETO2 overexpression upregulated and re-
pressed 182 and 51 miRNAs ( > 1.5-fold), respectively ( Suppl. Ta-
ble 1 ). Unexpectedly, we did not observe signiﬁcant expression
changes in miRNAs implicated in erythroid differentiation, such as
miR-150 (which affects Myb) [ 24 ], miR-223 (LMO2) [ 25 ], miR-191
(Riok3 and Mxi1) [ 26 ], as well as GATA-1-regulated miR-144 and 451
[ 18 ] ( Suppl. Table 1 ). Quantitative RT-PCR-based validation analysis
demonstrated signiﬁcant upregulation of miR-21, miR-29b and let-
7e, and downregulation of miR-19b-1*, whereas miR-20 and miR-15b
were unaffected by ETO2 overexpression ( Fig. 1 A). Interestingly, if we
set the cutoff value > 100 based on miRNA expression level, ETO2
overexpression downregulated the expression of only 7.0% of mature
miRNAs ( Fig. 1 B). 
We next conducted siRNA-mediated ETO2 knockdown in K562
cells ( Fig. 2 A), and conﬁrmed signiﬁcant downregulation of miR-21,
miR-29b, and let-7e by ETO2 knockdown ( Fig. 2 B), suggesting that
ETO2 positively regulates the expression of these miRNAs. In addi-
tion, miRNA proﬁling analysis identiﬁed miR-223 among the down-
regulated miRNA ensemble (1.7-fold, Suppl. Table 2 ), which was re-
ported to inhibit LMO2 expression by directly binding to LMO2 3 ′ -
untranslated region (3 ′ -UTR) [ 25 ]. As ETO2 level decreases with ery-
throid differentiation [ 12 ], the decrease may contribute to the reduc-
tion of miR-223 level, leading to increased LMO2 expression to pro-
mote erythroid differentiation [ 25 ]. The results of miRNA proﬁling
analysis indicated that ETO2 knockdown upregulated and repressed
2 and 105 miRNAs ( > 1.4-fold), respectively ( Suppl. Table 2 ). Further-
more, if we set the cutoff value > 100 based on miRNA expression
level, ETO2 knockdown exclusively downregulated miRNAs ( Fig. 2 C),
which supports the results of ETO2 overexpression ( Fig. 1 ). Taken
together, our results suggest that ETO2 positively regulates the abun-
dance of mature miRNAs. 
As ETO2 is known as a transcriptional corepressor [ 7 –12 ], it is
difﬁcult to consider that the ETO2-associated miRNA abundance was
attributable to the consequences of ETO2-mediated direct transcrip-
tional activation of target pre-miRNA transcripts. On the other hand,
a previous study indicated that overexpression of HDAC1 downreg-
ulated only 9.0% of regulated miRNAs [ 27 ], which was similar to our
observations with ETO2 overexpression ( Fig. 1 ). This previous study
also indicated that HDAC1 enhances miRNA processing via deacety-
lation of Drosha / DGCR8 [ 27 ]. Thus, based on the observations that
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Fig. 1. miRNA proﬁling in ETO2-overexpressing K562 cells. (A) Quantitative RT-PCR 
validation of array results for ETO2-regulated miRNAs ( Suppl. Table 1 ). The data are 
expressed as means ± SE ( n = 6). * P < 0.05. (B) Pie chart analysis denoting the percent- 
age of upregulated or downregulated miRNAs after ETO2 overexpression. We deﬁned 
















Fig. 2. miRNA proﬁling in ETO2-silenced K562 cells. (A) Quantitative RT-PCR (left) and 
Western blotting of whole-cell extracts (right) in ETO2 knockdown K562 cells. Anti- 
ETO2 antibody was used for the analysis. The expression of ETO2 relative to that of 
GAPDH was calculated ( n = 3, mean ± SE). α-Tubulin was used as a loading control. 
* P < 0.05. (B) Quantitative RT-PCR analysis for ETO2-regulated miRNAs ( Fig. 1 A). The 
data are expressed as means ± SE ( n = 6). * P < 0.05. (C) Pie chart analysis indicat- 
ing the percentage of upregulated or downregulated miRNAs after ETO2 knockdown. 
We deﬁned > 1.4-fold changes and an expression cutoff > 100. Downregulated miRNA 
included miR-223. 
 TO2 directly associates with HDAC1 [ 10 ] and exerts RNA binding 
roperties [ 23 ], we speculate that ETO2 may promote processing of 
 subset of miRNAs, leading to transcriptional / translational repres- 
ion. However, we cannot exclude the possibility that ETO2 directly 
epresses other factors, which might lead to the increased pre-miRNA 
ranscripts, which warrants further analyses. Taken together, our data 
uggest a novel mode of ETO2-mediated target gene repression by af- 
ecting miRNA. 
We demonstrated that ETO2 positively regulates the expression 
f miR-21, miR-29b, and let-7e based on the K562 erythroid cell line 
 Figs. 1 and 2 ). However, the phenotypic and karyotypic differences 
etween K562 cells and normal erythroblasts limit the importance 
f our ﬁndings. Therefore, we also conﬁrmed these ﬁndings based on 
uman cord blood CD34-positive cell-derived primary erythroblasts. 
e used the identical RNA sample sets as used in our previous study, which demonstrated that ETO2 overexpression in primary erythrob- 
lasts signiﬁcantly decreases representative erythroid-related genes, 
such as HBB , HBA , and ALAS2 [ 12 ]. As shown in Fig. 3 A, ETO2 over-
expression resulted in signiﬁcant upregulation of miR-21, miR-29b, 
and let-7e, and downregulation of miR-19b-1*, whereas miR-20 and 
miR-15b were constant, which supports the possibility that it may be 
a universal or physiological phenomenon that ETO2 regulates these 
miRNAs in erythroid cells. Furthermore, we next examined the ex- 
pression of these miRNA during erythroid differentiation from CD34- 
positive cells, based on the identical RNA sample [ 12 ]. As shown in 
Fig. 3 B, we observed the modest upregulation of miR-21 and miR-15b, 
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Fig. 3. Quantitative RT-PCR analysis for ETO2-regulated miRNAs in primary erythrob- 
lasts. (A) Quantitative RT-PCR validation of array results for ETO2-regulated miRNAs 
( Figs. 1 A and 2 B), using the identical RNA sample sets of primary erythroblasts overex- 
pressed with ETO2 [ 12 ]. The data are expressed as means ± SE ( n = 6). * P < 0.05. (B) 
The table summarizes changes in expression of genes on days 4, 8 and 14 in CD34 + 
cell-derived primary erythroblasts (mean ± SE, n = 3), using the identical RNA sample 
sets of primary erythroblasts [ 12 ]. The changes in miRNA expression were quantiﬁed 
by the  threshold cycle ( C γ) method, and presented as fold changes as compared 


































































 while the obvious downregulation of miR19b-1*, during erythroid
differentiation. As ETO2 protein level peaked at day 4 and almost
diminished at the later stage of differentiation [ 12 ], the decrease of
miR-19b-1* at day 4 was consistent with our observations ( Fig. 3 B).
However, the reason why the expressions of miR-21, miR-29b and
let-7e at day 4 were constant remains unknown ( Fig. 3 B). We spec-
ulate that ETO2-independent regulatory mechanism might affect the
expression of these miRNAs during erythroid differentiation. Never-
theless, ETO2-mediated upregulation of miR-21, miR-29b, and let-7e
may have some important roles during erythroid differentiation. 
miR-21 and miR-29b have been reported to be involved in the de-
velopment of lymphoma / leukemia as well as cancer drug resistance
[ 28 –30 ], whereas their roles in erythropoiesis have remained elusive.
Recent evidence suggested that increased levels of miR-21 are seen in
patients with myelodysplastic syndrome (MDS), and treatment with
miR-21 inhibitor promotes erythropoiesis based on the mouse model
of bone marrow failure syndrome as well as in vitro analysis with pri-
mary MDS bone marrow progenitors [ 31 ]. The ﬁnding suggests that
ETO2 inhibits erythroid differentiation partly by increasing miR-21
level. In the context of the role of ETO2 in hematological malignan-
cies, ETO2 may be involved in the pathogenesis of MDS. In addition,
AML1–ETO2 fusion protein resulting from t(16;21)(q24;q22) translo-
cation has been associated with myeloid malignancies [ 32 ]. As the
fusion protein consists of the N-terminus region of AML1 and al-
most the entire coding region of ETO2 [ 32 ], the chimeric protein mayaffect miR-21 and miR-29b levels. On the other hand, the upregu-
lation of miRNA cluster 99b / let-7e / 125a suggests a possible role of
ETO2 in hematopoietic stem cell function and erythroid differentia-
tion [ 33 , 34 ]. 
In summary, our data suggest that ETO2 regulates the abundance
of mature miRNAs in erythroid cells. In addition to conferring his-
tone deacetylation of the target gene loci, ETO2 may contribute to
the repression of target genes by affecting miRNA levels. We consider
that these regulatory mechanisms may target networks of genes and
signaling pathways to accomplish the erythroid differentiation pro-
gram. 
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